Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection

Journal of Viral Hepatitis

Volumn 20, Issue 7, 2013, Pages 453-462

  Adeyemo, O ^a   Doi, H ^a   Rajender Reddy, K ^a   Kaplan, D E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

hepatitis C; interferon gamma; interferon stimulated gene; lymphocyte; silymarin; T cell

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; PHYTOHEMAGGLUTININ; PLACEBO; SILYMARIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANDIDA ALBICANS; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE EXPRESSION; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ADMINISTRATION, ORAL; CELL PROLIFERATION; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PLACEBOS; SILYMARIN; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84878536109     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12050     Document Type: Article

References (38)

1. Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J, et al,. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 2001; 33 (1): 267-276.
2. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, et al,. Impaired effector function of hepatitis C virus-specific CD8 + T cells in chronic hepatitis C virus infection. J Immunol 2002; 169 (6): 3447-3458.
3. Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, Schraut W, et al,. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 2003; 37 (5): 1189-1198.
4. Kaplan DE, Sugimoto K, Newton K, Valiga ME, Ikeda F, Aytaman A, et al,. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 2007; 132 (2): 654-666.
5. Barnes E, Harcourt G, Brown D, Lucas M, Phillips R, Dusheiko G, et al,. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002; 36 (3): 743-754.
6. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV,. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118 (2): 346-355.
7. Rahman F, Heller T, Sobao Y, Mizukoshi E, Nascimbeni M, Alter H, et al,. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004; 40 (1): 87-97.
8. Wiegand J, Jackel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, et al,. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40 (1): 98-107.
9. Kaplan DE, Sugimoto K, Ikeda F, Stadanlick J, Valiga M, Shetty K, et al,. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology 2005; 41 (6): 1365-1375.
10. Claassen MA, de Knegt RJ, Tilanus HW, Janssen HL, Boonstra A,. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol 2010; 52 (3): 315-321.
11. Kaplan DE, Ikeda F, Li Y, Nakamoto N, Ganesan S, Valiga ME, et al,. Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol 2008; 48 (6): 903-913.
12. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, et al,. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest 2004; 113 (7): 963-972.
13. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C,. Milk thistle for alcoholic and/or hepatitis B or C liver diseases-a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100 (11): 2583-2591.
14. Johnson VJ, He Q, Osuchowski MF, Sharma RP,. Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Med 2003; 69 (1): 44-49.
15. Johnson VJ, Osuchowski MF, He Q, Sharma RP,. Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: II. alterations in thymic differentiation correlate with changes in c-myc gene expression. Planta Med 2002; 68 (11): 961-965.
16. Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G,. Silibinin protects mice from T cell-dependent liver injury. J Hepatol 2003; 39 (3): 333-340.
17. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, et al,. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135 (5): 1561-15 67.
18. Biermer M, Berg T,. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. Gastroenterology 2009; 137 (1): 390-391.
19. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, et al,. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010; 51 (6): 1912-1921.
20. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, et al,. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 2010; 138 (2): 671-681.
21. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY,. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 2007; 132 (5): 1925-1936.
22. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, et al,. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 2012; 308 (3): 274-282.
23. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM,. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003; 38 (6): 1437-1448.
24. Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth EE, Alter HJ, et al,. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37 (3): 590-599.
25. Diepolder HM, Zachoval R, Hoffmann RM, Jung MC, Gerlach T, Pape GR,. The role of hepatitis C virus specific CD4 + T lymphocytes in acute and chronic hepatitis C. J Mol Med 1996; 74 (10): 583-588.
26. Missale G, Cariani E, Lamonaca V, Ravaggi A, Rossini A, Bertoni R, et al,. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 1997; 26 (3): 792-797.
27. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al,. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117 (4): 933-941.
28. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, et al,. Interferon (IFN)- gamma -inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN- alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194 (7): 895-903.
29. Flora K, Hahn M, Rosen H, Benner K,. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998; 93 (2): 139-143.
30. Gharagozloo M, Amirghofran Z,. Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells. J Cancer Res Clin Oncol 2007; 133 (8): 525-532.
31. Polyak SJ, Morishima C, Hawke R,. Antiviral effects of silymarin against hepatitis C: the jury is still out. Hepatology 2008; 48 (1): 345-346.
32. Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, et al,. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Ther 2011; 33 (1): 127-137.
33. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, et al,. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol 2010; 50 (4): 434-449.
34. Deak G, Muzes G, Lang I, Nekam K, Gonzalez-Cabello R, Gergely P, et al,. Effects of two bioflavonoids on certain cellular immune reactions in vitro. Acta Physiol Hung 1990; 76 (2): 113-121.
35. Meroni PL, Barcellini W, Borghi MO, Vismara A, Ferraro G, Ciani D, et al,. Silybin inhibition of human T-lymphocyte activation. Int J Tissue React 1988; 10 (3): 177-181.
36. Chen L, Borozan I, Sun J, Guindi M, Fischer S, Feld J, et al,. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 2010; 138 (3): 1123-1133.
37. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al,. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46 (5): 1548-1563.
38. Rutter K, Scherzer TM, Beinhardt S, Kerschner H, Stattermayer AF, Hofer H, et al,. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. Antivir Ther 2011; 16 (8): 1327-1333.